Here are five takeaways:
1. Stability Biologics, founded in 2010 and headquartered in Nashville, is a provider of human tissue products to surgeons, facilities and distributors serving the surgical, spine and orthopedics sectors of the healthcare industry.
2. MiMedx expects the transaction to be accretive to Full Year Adjusted EPS in 2016, and it projects the 2016 Stability Biologics revenues generated from its processed tissue and bone product sales and distribution to be at least $15 million.
3. The transaction is subject to customary conditions of closing, which is expected to occur by mid-January 2016.
4. Following the transaction, Stability Biologics will operate as a wholly-owned subsidiary of MiMedx.
5. MiMedx is a regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for wound care, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare.
More articles on devices and implants:
US spinal surgery market outlook to 2021 — 5 things to know
NuVasive, Smith & Nephew, Medtech & more: 21 key notes
Conmed completes $265M SurgiQuest acquisition: 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
